WO1999061028A1 - Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine - Google Patents

Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine Download PDF

Info

Publication number
WO1999061028A1
WO1999061028A1 PCT/US1999/011532 US9911532W WO9961028A1 WO 1999061028 A1 WO1999061028 A1 WO 1999061028A1 US 9911532 W US9911532 W US 9911532W WO 9961028 A1 WO9961028 A1 WO 9961028A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
isoflavonoid
isoflavonoids
dietary product
migraine headaches
Prior art date
Application number
PCT/US1999/011532
Other languages
English (en)
Inventor
Sherwood L. Gorbach
Barry R. Goldin
Original Assignee
Gorbach Sherwood L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gorbach Sherwood L filed Critical Gorbach Sherwood L
Priority to EP99925828A priority Critical patent/EP1082122A4/fr
Priority to CA002333556A priority patent/CA2333556A1/fr
Priority to AU42040/99A priority patent/AU4204099A/en
Publication of WO1999061028A1 publication Critical patent/WO1999061028A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Definitions

  • the present invention relates to therapies for the prevention and treatment of migraine headaches and menstrual-related headaches and the symptoms associated with these headaches, particularly in women.
  • Migraine headaches are characterized by some (but not necessarily all) of the following symptoms: unilateral onset of headache; moderate to severe throbbing or pulsating head pain; photophobia (light sensitivity); premonitory aura of visual changes (blurry vision and/or flashing lights); speech difficulties; and hemiparesis (weakness or paralysis on one side). Approximately 20% of individuals experiencing a migraine headache report symptoms for a duration of four to six hours and 80% report a duration of six hours to more than twenty-four hours. In the United States between 17 and 19% of women have experienced symptoms of migraine headaches or menstrual-related headaches.
  • migraine headaches In women, about 60% of migraine headaches occur at plus or minus a two-day interval from onset of menstruation. The high frequency of migraine at menstruation is believed to result from the rapid decrease of estrogens in the blood at this time in the menstrual cycle.
  • migraine headaches are less common than in Western countries.
  • the incidence of migraine headaches among Japanese women is 40% lower than the incidence among American women.
  • the incidence of migraine headaches among elderly Chinese women is approximately 50% lower than that among age-matched American women.
  • Blood levels and urinary excretion of isoflavonoids have been studied in different population groups eating a regular diet containing either high or low amounts of isoflavonoids.
  • Japanese women who consumed soy products on a regular basis excreted 12 to 64 times more daidzein and 41 to 59 times more equol than American or Finnish women.
  • the invention features the use of purified isoflavonoids, which are constituents of soy beans and other plants such as clover, to effectively treat and prevent symptoms of headaches, in particular migraine headaches, that are caused by reduced or altered levels of endogenous estrogen. Migraine-like headaches in men are also treated with purified isoflavonoids according to the invention. Without being bound by any theory, it is believed that the isoflavonoids bind to estrogen receptors and activate cellular signal induction, and thus exert an estrogenic response. These compounds are safe and cause no significant side-effects.
  • Purified isoflavonoids which may be administered according to the invention include genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitein, equol and dihydrodaidzein and their conjugates; these may be administered alone or in combination.
  • the invention provides a method for treating or preventing symptoms of migraine headache by administering (preferably orally) to the person a composition containing one or more purified isoflavonoids selected from the group consisting of genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitein, equol, and dihydrodaidzein and their conjugates in an amount sufficient to produce a transient isoflavonoid concentration in the bloodstream of the person of at least 10 ng/ml.
  • the composition is administered orally, providing a dosage of at least 20 mg of total isoflavonoid per serving.
  • the orally-administrable composition can be a non-naturally occurring dietary product such as a confectionary bar, cereal, biscuit, or beverage.
  • the composition can take the form of a medicament such as a pill, capsule, tablet, powder, or syrup, in which the total isoflavonoid is present in at least an amount of 20 mg per unit dose.
  • the dietary product or medicament is orally consumed by the person once, twice, or three times per day, to provide a daily oral isoflavonoid dose of between 20 and 300 mg.
  • the oral ingestion of the composition is sufficient to produce in the bloodstream of the person a transient concentration of total isoflavonoid of at least 10 ng/ml.
  • purified isoflavonoid is meant an isoflavonoid in more concentrated form than occurs in plants.
  • each isoflavonoid administered according to the invention is at least 3%, more preferably at least 30% pure by weight.
  • the isoflavonoid-containing composition can be included in a transdermal delivery system or patch.
  • Isoflavonoids are naturally occurring compounds, found primarily in soy beans. These compounds are also found in high concentrations in red clover and in lower amounts in many other types of plants.
  • An isoflavonoid- containing fraction (containing purified isoflavonoids) useful in the invention can be extracted from a soy or plant product using known methods. It is preferred that the isoflavonoids be extracted and concentrated from soy beans or soy powder, but other plants such as clover can be used.
  • An isoflavonoid- containing fraction can be extracted from a soy or plant product in concentrations between 3 and 30% isoflavonoids. Isoflavonoids are also available commercially in substantially pure form.
  • the concentrated isoflavonoid is preferably administered either in pill, capsule, tablet, powder, or syrup form, or as an additive to a flavored drink, or as a component of a confectionary bar, biscuit, or cereal containing suitable flavoring to constitute a palatable product.
  • An isoflavonoid-containing transdermal patch can be of conventional form, e.g., that used to deliver sustained doses of nicotine or estrogen.
  • Isoflavonoids have similar chemical properties to estrogens, e.g., they are poorly soluble in water but are readily soluble in alcohols and other organic solvents.
  • the isoflavonoid is mixed in a base with ingredients such as alcohol, mineral oil, glyceryl monostearate, an ether complex of fatty acids, acetyl alcohol, lanolin, propylene glycol, stearyl alcohol, and sodium lauryl sulfate.
  • concentration of isoflavonoid is 1 to 40 mg per gram of the base, more preferably 10 to 25 mg per gram of base.
  • Other embodiments are within the claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement ou de prévention, chez une personne, d'un ou de plusieurs symptômes de céphalées du type migraine, ce procédé consistant à administrer à cette personne, oralement ou au moyen d'un système ou timbre transdermique, une composition comprenant un ou plusieurs isoflavonoïdes purifiés, choisis dans le groupe constitué par génistéine, daïdzéine, biochanine A, formononétine, O-desméthylangolensine, glycitéine, équol et dihydrodaïdzéine, et les conjugués de ceux-ci.
PCT/US1999/011532 1998-05-27 1999-05-25 Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine WO1999061028A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99925828A EP1082122A4 (fr) 1998-05-27 1999-05-25 Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine
CA002333556A CA2333556A1 (fr) 1998-05-27 1999-05-25 Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine
AU42040/99A AU4204099A (en) 1998-05-27 1999-05-25 Isoflavonoids for treatment and prevention of migraine headaches

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8548098A 1998-05-27 1998-05-27
US09/085,480 1998-05-27

Publications (1)

Publication Number Publication Date
WO1999061028A1 true WO1999061028A1 (fr) 1999-12-02

Family

ID=22191888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/011532 WO1999061028A1 (fr) 1998-05-27 1999-05-25 Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine

Country Status (4)

Country Link
EP (1) EP1082122A4 (fr)
AU (1) AU4204099A (fr)
CA (1) CA2333556A1 (fr)
WO (1) WO1999061028A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132084A1 (fr) * 2000-03-06 2001-09-12 Docteur Nature Srl Dispositif d'administration transdermique destiné à la libération lente de phytoestrogènes provenant de soja
WO2003072090A2 (fr) * 2002-02-27 2003-09-04 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de troubles du snc
WO2004103411A1 (fr) * 2003-05-23 2004-12-02 Migco Limited Remede contre la migraine
WO2006020166A1 (fr) * 2004-07-23 2006-02-23 The Procter & Gamble Company Dispositif de soin cutané à base de substrat
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
US7727731B2 (en) 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
US7741335B2 (en) 2001-06-29 2010-06-22 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US5807586A (en) * 1996-07-30 1998-09-15 Energetics, Inc. Method of dietary supplementation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US5807586A (en) * 1996-07-30 1998-09-15 Energetics, Inc. Method of dietary supplementation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EUROPATFUL ON STN, AN 765668, BREATON et al., "Extract of Iridaceas and Compositions Containing It"; & EP 765668 B1, 17 March 1999. *
See also references of EP1082122A4 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132084A1 (fr) * 2000-03-06 2001-09-12 Docteur Nature Srl Dispositif d'administration transdermique destiné à la libération lente de phytoestrogènes provenant de soja
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
US7741335B2 (en) 2001-06-29 2010-06-22 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
US7727731B2 (en) 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
US7700610B2 (en) 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
WO2003072090A2 (fr) * 2002-02-27 2003-09-04 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de troubles du snc
WO2003072090A3 (fr) * 2002-02-27 2003-11-13 Ab Science Utilisation d'inhibiteurs de tyrosine kinase pour le traitement de troubles du snc
US9173866B2 (en) 2002-07-24 2015-11-03 Children's Hospital Medical Center Compositions and products containing R-equol, and methods for their making
US7396855B2 (en) 2002-07-24 2008-07-08 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US9018247B2 (en) 2002-07-24 2015-04-28 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US7960432B2 (en) 2002-07-24 2011-06-14 Children's Hospital Medical Center Compositions and products containing S-equol, and methods for their making
US8048913B2 (en) 2002-07-24 2011-11-01 Australian Health & Nutrition Assoc. Ltd. Compositions and products containing S-equol, and methods for their making
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US8450364B2 (en) 2002-10-29 2013-05-28 Brigham Young University Use of equol for treating androgen mediated diseases
US8153684B2 (en) 2002-10-29 2012-04-10 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US9089547B2 (en) 2002-10-29 2015-07-28 Brigham Young University Use of equol for treating androgen mediated diseases
US9408825B2 (en) 2002-10-29 2016-08-09 Brigham Young University Use of equol for treating androgen mediated diseases
US9889116B2 (en) 2002-10-29 2018-02-13 Bringham Young University Use of equol for treating androgen mediated diseases
US10111855B2 (en) 2002-10-29 2018-10-30 Brigham Young University Use of equol for treating androgen mediated diseases
JP2007501856A (ja) * 2003-05-23 2007-02-01 ミグコー・リミテッド 片頭痛治療薬
WO2004103411A1 (fr) * 2003-05-23 2004-12-02 Migco Limited Remede contre la migraine
WO2006020166A1 (fr) * 2004-07-23 2006-02-23 The Procter & Gamble Company Dispositif de soin cutané à base de substrat

Also Published As

Publication number Publication date
EP1082122A4 (fr) 2003-04-09
AU4204099A (en) 1999-12-13
EP1082122A1 (fr) 2001-03-14
CA2333556A1 (fr) 1999-12-02

Similar Documents

Publication Publication Date Title
US5498631A (en) Method for treatment of menopausal and premenstrual symptoms
US5733926A (en) Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
EP0656786B1 (fr) Utilisation d'extraits des phyto-estrogenes d'isoflavones a partir de soja ou de trefle
CA2287965C (fr) Traitement ou prevention des symptomes menopausiques et de l'osteoporose
US6060070A (en) Isoflavonoids for treatment and prevention of aging skin and wrinkles
US4886665A (en) Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care
US6083526A (en) Use of isoflavonoids in the treatment or prevention of postpartum depression
JP2003245054A (ja) 健康食品
EP1082122A1 (fr) Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine
CN100366628C (zh) 槐角黄酮有效部位、生产方法及其应用
US20070059393A1 (en) Composition for inhibition or prevention of bone density
WO2007042745A1 (fr) Suppresseur d'appetit a base de chocolat
KR20100129571A (ko) 정자수 증가와 환경호르몬 예방효과를 갖는 성기능 개선 조성물 및 이를 함유하는 성기능 개선용 식품
JPH08231533A (ja) 新規フラボノイド配糖体およびフラボノイド配糖体を含む骨粗鬆症治療剤ならびに可食性組成物
Montanari et al. Health promoting phytochemicals in citrus fruit and juice products
JP2004210675A (ja) 骨量改善組成物
JP2004196751A (ja) 更年期症状改善組成物
WO2001087315A1 (fr) Traitement ou prevention d'affection metabolique osseuse
WO2006003750A1 (fr) Agent anti-inflammatoire/préventif de l'inflammation, produit pharmaceutique, aliment ou boisson et parfum ou cosmétique
AU777632B2 (en) Health supplements containing isoflavones
AU7017198A (en) Treatment or prevention of menopausal symptoms and osteoporosis
AU2004224983A1 (en) Health supplements containing isoflavones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2333556

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 42040/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999925828

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999925828

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999925828

Country of ref document: EP